Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged ≥18 years old.~* Written informed consent.~* Association of the 3 following criteria:~  1. Both eyes have primary open angle glaucoma or ocular hypertension already treated and controlled by mono-therapy of Lumigan® 0.01% since at least 3 months (according to European Glaucoma Society guidelines).~ 2. Intra Ocular Pressure ≤ 18 mm Hg in both eyes.~ 3. With local intolerance signs in at least one eye defined by the association of:~3.1 Hyperaemia = Grade (2) or (3) or (4) following the photographic MacMonnies scale.~And 3.2.1 Presence of at least 2 symptoms with a level of severity ≥ 1 (= mild or moderate or severe) among the following 5 symptoms: irritation/burning, itching, tearing, eye dryness sensation, foreign body sensation.~And/Or 3.2.2 Presence of at least 2 signs with a level of severity ≥ 1 (= mild or moderate or severe) among the following 3 signs: superficial punctate keratitis, blepharitis, eyelid skin darkness.~Exclusion Criteria:~* - Presence of at least one severe objective sign among the following:~  * Global ocular staining with Oxford (0-15) grading scheme \>12.~ * Blepharitis (Grade 4: Very severe, i.e. eczematiform lesion).~* Any ocular hypertension other than primary ocular hypertension or primary chronic open angle glaucoma (such as congenital, angle closure glaucoma, secondary glaucoma).~* Visual field not performed or not available within the 6 months before inclusion visit.~* Fundus not performed or not available within the 6 months before inclusion visit.~* Advanced stage of glaucoma:~  * Absolute defect in the ten degrees central point of the visual field.~ * Severe visual field loss according to the investigator's best judgement.~ * Risk of visual field worsening as a consequence of participation in the trial according to the investigator's best judgement.~* Best far corrected visual acuity ≤ 1/10.~* History of trauma, infection, inflammation within the 3 months before inclusion visit.~* Ongoing or known history of ocular allergy and/or uveitis and/or viral infection.~* Severe dry eye (defined by severe epithelial erosions of the cornea and/or use of dry eye medication with a frequency exceeding 8 instillations / day).~* Corneal ulceration.~* Palpebral abnormalities not related to medical treatment study and incompatible with a good evaluation.~* Any abnormality preventing accurate assessment e.g. reliable tonometry measurement, visual field examination.~Systemic/non ophthalmic/ exclusion criteria~* Non-controlled diabetic patient.~* Known or suspected hypersensitivity to one of the components of the study product.~* Any medical or surgical history, disorder or disease such as acute or chronic severe organic disease: hepatic, endocrine, neoplastic, haematological; immunosuppressive, infectious diseases, severe psychiatric illness, relevant cardiovascular abnormalities, etc... and/or any complicating factor or structural abnormality, judged by the investigator to be incompatible with the study.~Specific exclusion criteria for women~* Pregnancy, lactation.~* Childbearing potential woman who is not using a reliable method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch) and is not surgically sterilised.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Monoprost (Type: EXPERIMENTAL): 1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
- Lumigan 0.01% (Type: ACTIVE_COMPARATOR): 1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.
- Lumigan 0.03% Unit Dose (Type: ACTIVE_COMPARATOR): 1 drop in each eye once daily at 9.00 pm (± 1 hour) for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).